Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive(R) under Expanded Immunization

Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis
            Vaccine Healive(R) under Expanded Immunization Program

PR Newswire

BEIJING, Nov. 7, 2013

BEIJING, Nov. 7, 2013 /PRNewswire/ --Sinovac Biotech Ltd. (NASDAQ: SVA), a
leading China-based vaccine manufacturer, announced today that it has been
selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu
CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under
the Expanded Program of Immunization (EPI) in 2014 to the pediatric population
in Jiangsu Province. The total volume of the tender is up to 1.8 million
doses.As one of the two selected suppliers, Sinovac will supply 900,000 doses
of Healive to Jiangsu province.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are
pleased to be selected once again by the Jiangsu CDC as one of the two
suppliers of inactivated hepatitis A vaccine pursuant to the tender for the
2014 EPI. We are advancing our strategy to collaborate with the government
agencies to provide top-quality vaccines to prevent and control diseases in
China and beyond."

Healive is the first inactivated hepatitis A vaccine developed, produced and
marketed by a China-based manufacturer. Healive was launched by Sinovac in
2002 in China and is currently available in adult and pediatric dosage forms.
In February 2008, the Chinese government included hepatitis A vaccine in its
national immunization program.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease) and filed the new drug application with China
Food & Drug Administration. In 2009, Sinovac was the first company worldwide
to receive approval for its H1N1 influenza vaccine, Panflu.1, and has
manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program.The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.

Stephanie Carrington
The Ruth Group

Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028

SOURCE Sinovac Biotech Ltd.

Press spacebar to pause and continue. Press esc to stop.